Juvenile Diabetes Market Scope
Juvenile diabetes, also known as type 1 diabetes or diabetes mellitus, is most often diagnosed in children and millennial whose bodies do not make insulin. Millions of people across the globe live with diabetes or know someone living with diabetes. The majority have type 2 diabetes, but an important minority have type 1 diabetes (approx. 5 percent). Unhealthy food habits, rising obesity rates, and sedentary lifestyle are key contributing factors fuelling the growth of global juvenile diabetes market.
According to AMA, the Global Juvenile Diabetes market is expected to see growth rate of 6.17%
The Players having a strong hold in the market are Novo Nordisk (Denmark), AstraZeneca PLC. (United Kingdom), Sanofi (France). Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Juvenile Diabetes market throughout the predicted period.
Eli Lilly and Company (United States), Bayer Pharmaceuticals (Germany), Sanofi (France), Novo Nordisk (Denmark), AstraZeneca PLC. (United Kingdom), XOMA Corp (United States), DiaVacs Inc. (United States), B.BraunMelsungen AG (Germany), Biodel Inc. (United States), Macrogenics Inc. (United States), Takeda Pharmaceutical (Japan) and Wockhardt Ltd. (India) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
The study have segmented the market of Global Juvenile Diabetes market by Type (Drugs and Delivery Devices), by Application (Hospitals, Clinics and Medical Centers) and Region with country level break-up.
On the basis of geography, the market of Juvenile Diabetes has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In 2018, Medtronic plc acquired Nutrino Health Ltd. (Israel). This acquisition strengthened Metronicís CGM and industry-leading hybrid closed-loop systems portfolio in the digital diabetes management market
- Technological Advancements in HI Delivery Devices
- Increasing Demand for Artificial Pancreas and Home Infusion Therapy for Diabetes Treatment
- Increasing Rate of Advances in Insulin Delivery Devices
- Growth in the Number of Juvenile Diabetic Patients in Developed Economies
- Strong Pipeline and Development of Molecules from Newer Class of Diabetes Drugs
- Favorable Medical Reimbursement Scenario in Developed Countries
- High Cost of Diagnosis and Treatment
- Side Effects Associated with the Treatment Therapies of Juvenile Diabetes
- Stringent Regulatory Requirements for Product Approval
- High Product Manufacturing Costs
Key Target AudienceOriginal Equipment Manufacturers (OEMs), Healthcare Service Providers, Research Laboratories and Academic Institutes, Product Sales and Distribution Companies, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations (CROs), Research and Development Companies and Others